Stephen A. Jannetti

Stephen A. Jannetti

Auto-generated profile, based on publicly available information

Stephen A. Jannetti

Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2020 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
GPGiacomo Pirovano
Giacomo Pirovano
SJStephen A. Jannetti
Stephen A. Jannetti
LCLukas M Carter
Lukas M Carter
ASAhmad Sadique
Ahmad Sadique
SKSusanne Kossatz
Susanne Kossatz
TRThomas Reiner
Thomas Reiner
Purpose: Glioblastoma multiforme is a highly aggressive form of brain cancer whose location, tendency to infiltrate healthy surrounding tissue, and heterogeneity significantly limit survival, with scant progress having been made in recent decades. Experimental Design: 123I-MAPi (Iodine-123 Meitner-Auger PARP1 inhibitor) is a precise therapeutic tool composed of a PARP1 inhibitor radiolabeled with an Auger- and gamma-emitting iodine isotope. Here, the PARP inhibitor, which binds to the DNA repair enzyme PARP1, specifically targets cancer cells, sparing healthy tissue, and carries a radioactive payload within reach of the cancer cells' DNA. Results: The high relative biological efficacy of Auger electrons within their short range of action is leveraged to inflict DNA damage and cell death with high precision. The gamma ray emission of 123I-MAPi allows for the imaging of tumor progression and therapy response, and for patient dosimetry calculation. Here we demonstrated the efficacy and specificity of this small-molecule radiotheranostic in a complex preclinical model. In vitro and in vivo studies demonstrate high tumor uptake and a prolonged survival in mice treated with 123I-MAPi when compared with vehicle controls. Different methods of drug delivery were investigated to develop this technology for clinical applications, including convection enhanced delivery and intrathecal injection. Conclusions: Taken together, these results represent the first full characterization of an Auger-emitting PARP inhibitor which demonstrate a survival benefit in mouse models of GBM and confirm the high potential of 123I-MAPi for clinical translation.

2 July 2020 in International Journal of Radiation Biology
Verified
Journal Article
Open access
TWThomas C. Wilson
Thomas C. Wilson
SJStephen A. Jannetti
Stephen A. Jannetti
NGNavjot Guru
Navjot Guru
NPNagavarakishore Pillarsetty
Nagavarakishore Pillarsetty
TRThomas Reiner
Thomas Reiner
GPGiacomo Pirovano
Giacomo Pirovano
Purpose: 123I-MAPi, a novel PARP1-targeted Auger radiotherapeutic has shown promising results in pre-clinical glioma model. Currently, 123I-MAPi is synthesized using multistep synthesis that results in modest yields and low molar activities (MA) that limits the ability to translate this technology for human studies where high doses are administered. Therefore, new methods are needed to synthesize 123I-MAPi in high activity yields (AY) and improved MA to facilitate clinical translation and multicenter trials. Materials and methods: 123I-MAPi was prepared in a single step via 123I-iododetannylation of the corresponding tributylstannane precursor. In vitro internalization assay, subcellular fractionation and confocal microscopy where used to evaluate the performance of 123I-MAPi in a small cell lung cancer model. Results: 123I-MAPi was synthesized in a single step from the corresponding stannane precursor in AY of 45 ± 2% and MA of 11.8 ± 4.8 GBq µmol−1. In vitro in LX22 cells showed rapid internalization (5 min) with accumulation found predominantly in the membrane, nucleus and chromatin of the cell as determined by subcellular fractionation. Conclusions: Here, we have developed an improved radiosynthesis of 123I-MAPi, an Auger theranostic agent. This process was achieved using a single step, 123I-iododestannylation reaction from the corresponding stannane precursor in good AY and MA. 123I-MAPi was evaluated in vitro in a small cell lung cancer model with high PARP expression, rapid internalization and high nuclear uptake shown.

24 May 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
GPGiacomo Pirovano
Giacomo Pirovano
SJStephen A. Jannetti
Stephen A. Jannetti
LCLukas M. Carter
Lukas M. Carter
ASAhmad Sadique
Ahmad Sadique
SKSusanne Kossatz
Susanne Kossatz
TRThomas Reiner
Thomas Reiner
Glioblastoma multiforme is a highly aggressive form of brain cancer whose location, tendency to infiltrate healthy surrounding tissue, and heterogeneity significantly limit survival, with scant progress having been made in recent decades. 123 I-MAPi (Iodine-123 Meitner-Auger PARP1 inhibitor) is a precise therapeutic tool composed of a PARP1 inhibitor radiolabeled with an Auger- and gamma-emitting iodine isotope. Here, the PARP inhibitor, which binds to the DNA repair enzyme PARP1, specifically targets cancer cells, sparing healthy tissue, and carries a radioactive payload within reach of the cancer cells’ DNA. The high relative biological efficacy of Auger electrons within their short range of action is leveraged to inflict DNA damage and cell death with high precision. The gamma ray emission of 123 I-MAPi allows for the imaging of tumor progression and therapy response, and for patient dosimetry calculation. Here we demonstrated the efficacy and specificity of this small molecule radiotheranostic in a complex preclinical model. In vitro and in vivo studies demonstrate high tumor uptake and a prolonged survival in mice treated with 123 I-MAPi when compared to vehicle controls. Different methods of drug delivery were investigated to develop this technology for clinical applications, including convection enhanced delivery (CED) and intrathecal injection. Taken together, these results represent the first full characterization of an Auger-emitting PARP inhibitor, demonstrate a survival benefit in mouse models of GBM, and confirm the high potential of 123 I-MAPi for clinical translation. One Sentence Summary: A novel PARP1-targeted Auger radiotherapeutic shows translational potential as a theranostic tool for imaging and killing cancer cells, resulting in tumor delineation and prolonged survival in a glioblastoma model.

31 March 2023
Verified
Other
Open access
GPGiacomo Pirovano
Giacomo Pirovano
SJStephen A. Jannetti
Stephen A. Jannetti
LCLukas M Carter
Lukas M Carter
ASAhmad Sadique
Ahmad Sadique
SKSusanne Kossatz
Susanne Kossatz
TRThomas Reiner
Thomas Reiner
Purpose:Glioblastoma multiforme is a highly aggressive form of brain cancer whose location, tendency to infiltrate healthy surrounding tissue, and heterogeneity significantly limit survival, with scant progress having been made in recent decades.Experimental Design:123I-MAPi (Iodine-123 Meitner-Auger PARP1 inhibitor) is a precise therapeutic tool composed of a PARP1 inhibitor radiolabeled with an Auger- and gamma-emitting iodine isotope. Here, the PARP inhibitor, which binds to the DNA repair enzyme PARP1, specifically targets cancer cells, sparing healthy tissue, and carries a radioactive payload within reach of the cancer cells' DNA.Results:The high relative biological efficacy of Auger electrons within their short range of action is leveraged to inflict DNA damage and cell death with high precision. The gamma ray emission of 123I-MAPi allows for the imaging of tumor progression and therapy response, and for patient dosimetry calculation. Here we demonstrated the efficacy and specificity of this small-molecule radiotheranostic in a complex preclinical model. In vitro and in vivo studies demonstrate high tumor uptake and a prolonged survival in mice treated with 123I-MAPi when compared with vehicle controls. Different methods of drug delivery were investigated to develop this technology for clinical applications, including convection enhanced delivery and intrathecal injection.Conclusions:Taken together, these results represent the first full characterization of an Auger-emitting PARP inhibitor which demonstrate a survival benefit in mouse models of GBM and confirm the high potential of 123I-MAPi for clinical translation.

31 March 2023
Verified
Other
Open access
GPGiacomo Pirovano
Giacomo Pirovano
SJStephen A. Jannetti
Stephen A. Jannetti
LCLukas M Carter
Lukas M Carter
ASAhmad Sadique
Ahmad Sadique
SKSusanne Kossatz
Susanne Kossatz
TRThomas Reiner
Thomas Reiner

31 March 2023
Verified
Other
Open access
GPGiacomo Pirovano
Giacomo Pirovano
SJStephen A. Jannetti
Stephen A. Jannetti
LCLukas M Carter
Lukas M Carter
ASAhmad Sadique
Ahmad Sadique
SKSusanne Kossatz
Susanne Kossatz
TRThomas Reiner
Thomas Reiner